More than 4,000 people with various forms of epilepsy will have their DNA decoded over the next five years in a study led by researchers at UCSF and several collaborating institutions.
January 23, 2012
January 18, 2012
Dogs with spinal cord injuries may soon benefit from an experimental drug being tested by researchers at UCSF and Texas A&M College of Veterinary Medicine & Biomedical Sciences — work that they hope will one day help people with similar injuries.
December 16, 2011
A large, international team of researchers led by scientists at UCSF has identified the gene that causes a rare childhood neurological disorder called PKD/IC, or “paroxysmal kinesigenic dyskinesia with infantile convulsions,” a cause of epilepsy in babies and movement disorders in older children.
November 14, 2011
November 01, 2011
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.
October 26, 2011
Three UCSF volunteers are leading a $25-million fundraising campaign to raise funds for brain cancer treatment and research.
October 26, 2011
The widow of the late Sen. Edward M. Kennedy joined a UCSF panel of caregivers and clinicians who recently explored ways of enhancing the quality of life and care of brain cancer patients.
October 24, 2011
A study by researchers at the University of Mississippi Medical Center and UCSF shows that rats given a popularly prescribed antidepressant during development exhibit brain abnormalities and behaviors characteristic of autism spectrum disorders.
October 19, 2011
Premature infants exposed after birth to drugs known as glucocorticoids are at increased risk for having impaired growth of the cerebellum, according to findings from a new UCSF-led study. The cerebellum is a region of the brain associated with balance, motor learning, language and behavior.
October 14, 2011
The only medication currently approved for stroke treatment – tissue plasminogen activator (tPA), which dissolves blood clots – is associated with an increased risk of bleeding in the brain, particularly among patients with hyperglycemia (high blood sugar).